SRL
TARS icon

Scientech Research LLC’s Tarsus Pharmaceuticals TARS Stock Holding History

Scientech Research LLC’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,619
Closed -$289K – 834
2024
Q2 		$289K Buy
+10,619
New +$357K 0.06% 459

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Scientech Research LLC's TARS Position: Q3 2024 in Review

Scientech Research LLC sold out of Tarsus Pharmaceuticals (TARS) in Q3 2024, closing a stake of 10,619 shares — an estimated $289K sold.

Scientech Research LLC first reported a position in TARS in Q2 2024 and held it in 1 quarter. The position peaked at $289K in Q2 2024. 162 funds tracked by Wall St. Rank hold TARS as of Q3 2024.

  • Scientech Research LLC reported no remaining Tarsus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Scientech Research LLC sold 10,619 Tarsus Pharmaceuticals shares in Q3 2024, an estimated $289K.
  • Scientech Research LLC first reported a position in Tarsus Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Scientech Research LLC's Tarsus Pharmaceuticals position peaked at $289K in Q2 2024.
  • 162 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2024.

Based on Scientech Research LLC's 13F filing for Q3 2024, filed 14 Nov 2024.